ArticleCureus2026
Assessment of Depression, Anxiety, and Quality of Life in Patients With Psoriasis Using the Dermatology Life Quality Index (DLQI) and Depression Anxiety Stress Scale-21 (DASS-21): A Cross-Sectional Study From Southern India.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Psoriasis is a chronic inflammatory skin disorder associated with significant psychosocial morbidity. Despite its visible nature and impact on daily functioning, data from India on the prevalence of depression and anxiety in psoriasis patients remains limited. This study aimed to evaluate psychological morbidity and its relationship with disease severity and quality of life (QoL) in patients with psoriasis. Methods A cross-sectional study was conducted among 63 adult patients with psoriasis attending a tertiary care teaching hospital in Southern India between February 2021 and August 2022. Patients aged 18-65 years with disease duration ≥12 months and without major comorbidities were included. Disease severity was assessed using the Psoriasis Area Severity Index (PASI), QoL was assessed using the Dermatology Life Quality Index (DLQI), and psychological status was assessed using the Depression Anxiety Stress Scale (DASS-21). Statistical analyses included independent t-test, Mann-Whitney U test, chi-square test, and Spearman correlation, with p<0.05 considered significant. Results The study population included 42 males (66.7%) and 21 females (33.3%). Female patients were significantly younger than males (34.8±11.9 vs. 44.5±13.1 years, respectively; p=0.006) and had higher DLQI scores (p=0.011). Depression and anxiety were observed in 22.2% and 9.5% of patients, respectively. PASI scores showed a weak positive correlation with DLQI (ρ=0.352; p=0.005). In contrast, DLQI demonstrated a moderate positive correlation with depression, anxiety, and stress scores (ρ=0.540-0.571; p<0.005). Family completion and prior systemic therapy were associated with significantly lower DLQI scores. Conclusion QoL correlates more strongly with psychological morbidity than with clinical severity in patients with psoriasis. Psychological burden appears to be only weakly associated with disease severity. Incorporating DLQI into routine dermatology practice may serve as a practical first-step screening tool, with higher scores prompting further evaluation using structured instruments such as DASS-21 and, where indicated, referral for psychiatric assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.